Dr. Daniel Karp, MD

• Hematology

• Medical Oncology

• Internal Medicine

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Duke University

  Medical School, 1973

• Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center, 2022-03-04

• Phase I Study of the Combination of Vemurafenib, Carboplatin, and Paclitaxel in Patients withBRAF-Mutated Melanoma and Other Advanced Malignancies, 2018-11-01

• Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study, 2021-10-27

• Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience, 2017-08-03

• Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study, 2021-09-25

• Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic, 2018-09-04

• A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation, 2023-06-14

• Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study, 2021-03-19

• Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience, 2016-11-23

• Associations between the gut microbiome and fatigue in cancer patients, 2021-03-12

• Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma, 2019-09-18

• Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors, 2017-11-21

• Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers, 2017-10-19

• Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors, 2021-12-29

• Vitamin E and the Risk of Prostate Cancer: Updated Results of The Selenium and Vitamin E Cancer Prevention Trial (SELECT), 2011-10-12

• Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study, 2021-11-03

• BRAFmutation testing with a rapid, fully integrated molecular diagnostics system, 2015-07-27

• Development and validation of an ultra-deep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer, 2017-05-23

• Phase II Study of Pembrolizumab Efficacy and Safety in Women with Recurrent Small Cell Neuroendocrine Carcinoma of the Lower Genital Tract, 2020-06-11

• Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology, 2022-10-27

• The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial, 2021-01-07

• Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection ofKRASMutations in Urine Cell-Free DNA from Patients with Advanced Cancers, 2017-01-17

• Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial, 2022-08-23

• Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period, 2023-02-07

• Phase I study of everolimus, letrozole, and trastuzumab in patients with hormone receptor-positive metastatic breast cancer or other solid tumors, 2020-10-28

• Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study, 2021-04-28